Last reviewed · How we verify
Autologous T cells-Based Immunotherapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous T cells-Based Immunotherapy (Autologous T cells-Based Immunotherapy) — Shanghai AbelZeta Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous T cells-Based Immunotherapy TARGET | Autologous T cells-Based Immunotherapy | Shanghai AbelZeta Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous T cells-Based Immunotherapy CI watch — RSS
- Autologous T cells-Based Immunotherapy CI watch — Atom
- Autologous T cells-Based Immunotherapy CI watch — JSON
- Autologous T cells-Based Immunotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Autologous T cells-Based Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-t-cells-based-immunotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab